Lonza Group

Lonza Group is a Swiss multinational life science company headquartered in Basel, Switzerland, founded in 1897, that is one of the world's leading contract development and manufacturing organizations (CDMOs) for pharmaceutical, biotech, and specialty ingredient markets. In the research and academic context, Lonza's most widely used products are the Nucleofector transfection systems and reagent kits, which use electroporation optimized for primary cells and hard-to-transfect cell lines that are resistant to lipid-based transfection. The Nucleofector technology has enabled functional genomics studies in neurons, cardiomyocytes, T cells, hematopoietic stem cells, and other primary cell types that were previously not amenable to gene delivery. Lonza's Clonetics and CC-series primary cell culture media and human primary cells (endothelial cells, smooth muscle cells, hepatocytes, keratinocytes) are reference materials for physiological cell culture research. Their BioResearch division provides accredited mycoplasma testing and biosafety testing for academic cell culture labs and cell therapy developers. On the CDMO side, Lonza's Mammalian cell culture, microbial fermentation, and ADC conjugation manufacturing capabilities are essential to biotechnology startups and academic licensing programs that need manufacturing partners to produce clinical-grade biologics for early-phase clinical trials. Their Ibex Solutions flexible manufacturing platform enables multiple products to share infrastructure, reducing costs for early-stage programs. Lonza's research into cell line development, including the proprietary GS (glutamine synthetase) expression system, has shaped how recombinant proteins are produced in CHO cells across the industry.